Human immunodeficiency virus associated lymphoma.

Human immunodeficiency virus (HIV) infection is known to be associated with an increased risk of systemic nonHodgkin lymphoma, Hodgkin disease, and primary central nervous lymphoma (PCNSL). The purpose of this review is to highlight recent advances in the diagnosis and management of lymphoma occurring in patients with HIV infection.
Lymphoma occurring in patients with HIV infection has been associated with a very poor prognosis. Recently reported studies have provided new information regarding the influence of highly active antiretroviral therapy (HAART) on the development and clinical presentation of lymphoma, the feasibility of combining HAART with standard chemotherapy, the molecular classification of lymphoma, the role of rituximab in the management of lymphoma, and the use of novel treatment strategies for the treatment of Hodgkin disease.
The improved prognosis for patients with HIV-associated lymphoma in the post-HAART era indicates that therapeutic interventions may be potentially curative, and represent a shift away from therapeutic nihilism and reduced-intensity treatment approaches that have been employed in the recent past.
AuthorsJoseph A Sparano
JournalCurrent opinion in oncology (Curr Opin Oncol) Vol. 15 Issue 5 Pg. 372-8 (Sep 2003) ISSN: 1040-8746 [Print] United States
PMID12960519 (Publication Type: Journal Article, Review)
Chemical References
  • Anti-HIV Agents
  • Antineoplastic Agents
  • Anti-HIV Agents (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Humans
  • Lymphoma, AIDS-Related (diagnosis, therapy)
  • Stem Cell Transplantation

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: